

Substitute for form 1449/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	53(b) Continuation of 10/224903
				Filing Date	August 21, 2002
				First Named Inventor	Michael W. Dunne
				Art Unit	As to Parent: 1623
				Examiner Name	As to Parent: Latonia M. Fisher
Sheet	1	of	1	Attorney Docket Number	PC 23140A (121*399)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	4,328,334	5/4/82	Kobrehel et al.	
	AB	4,474,768	10/2/84	Bright	
	AC	4,517,359	5/14/85	Kobrehel et al.	
	AD	4,963,531	10/16/90	Remington	
	AE	5,498,699	3/12/96	Djokic et al.	
	AF	5,605,889	2/25/97	Curatolo et al.	
	AG	5,633,006	5/27/97	Catania et al.	
	AH	5,686,587	11/11/97	Yang	
	AI	6,068,859	5/30/00	Curatolo et al.	
	AJ	6,268,489	7/31/01	Allen et al.	


FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					T <sup>6</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	AK	ARGUEDAS, A., Single-Dose Therapy in Otitis Media, Poster Presentation at 9 <sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, March 21-24, 1999, <i>Clin. Microbiol. Infect.</i> 1999;5 (Supp. 3 March):28 (Abstr).			
	AL	S. BLOCK ET AL., Single-Dose Azithromycin (30 mg/kg) in Acute Otitis Media, 38 <sup>th</sup> Annual Meeting of the Infectious Disease Society of America, New Orleans, LA, Sept. 7-10, 2000 (Abstract 174).			
	AM	P/S/L Consulting Group Inc., Single-Dose Zithromax (Azithromycin) as Effective as 10 Days of Augmentin (Amoxicillin/Clavulanate) for Otitis Media, Doctor's Guide; September 14, 2000.			
	AN	FDA Briefing Package: Zithromax® (Azithromycin) Oral Suspension Single-Dose and Three Day Treatment of Acute Otitis Media, Anti-Infective Drugs Advisory Committee, November 7, 2001.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	4/27/04
--------------------	---	-----------------	---------


[illegible]

<b>INFORMATION DISCLOSURE CITATION</b>  <i>(Use several sheets if necessary)</i>	<b>ATTY. DOCKET NO.</b> PC23140A (121*399)		<b>SERIAL NO.</b> 10/628,102
	<b>APPLICANT</b> Michael William Dunne		
	<b>FILING DATE</b> July 25, 2003		<b>GROUP</b> 1623

(P) 801 2 2004 (7) (P) 801 2 2004 (7)	Jacki N., Japanese Journal of Chemotherapy 1995, Japan, vol. 43, no. Suppl 6, pp. 234-238 XP008018296
	Morris, D.L., et al., , vol. 10, no. 10., Oct. 1991, pp. 859-861, European J. of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology, Germany XP008018299
	Klepser, M., et al., International J. of Antimicrobial Agents, vol. 17, no. Supp 1, June 2001, p. S157, 22nd International Congress of Chemotherapy; Amsterdam, June 30-July 3, 2001 XP002244592
	Bergogne-Berezin Eugenie, Pathologie Biologie, vol. 43, no. 6, 1995, pp. 498-504, "Azithromycin: Tissue pharmacokinetic data" XP008018308

<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> 1/7/2005
--	------------------------------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTD-FB-A820

INFORMATION DISCLOSURE